Enzymatica rang in the company at Nasdaq First North

Today at nine in the morning CEO Fredrik Lindberg rang the Nasdaq First North Stock Market opening bell in Stockholm, to mark the first day of trading for Enzymatica AB.

Enzymatica is a Swedish life science company whose business concept is to offer effective aid against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for common colds and launched it on four markets, and in winter it achieved the position as the most-sold article for common colds calculated in kronor in Swedish pharmacies.

"We now have a unique product that keeps colds at bay and makes life easier for many users. In two years we have moved from zero to number one in Swedish pharmacies and thanks to the listing we have a stable foundation for our continued work to establish ColdZyme internationally", says Fredrik Lindberg, CEO of Enzymatica.

"The listing is part of creating a long-term platform for Enzymatica's continued development. Through the listing the company gains a stamp of quality that is important for a small company that does business with larger actors. We now have the opportunity to position the company and create long-term contacts with the stock market, which gives scope for greater institutional ownership," says Lennart Nilsson, Chairman of the Board of Enzymatica.

ColdZyme has been on sale in Swedish pharmacies and health food stores since autumn 2013 and in 2014 was also made available in Norway, Denmark and the United Kingdom. With focus on building a strong Scandinavian domestic market with its own sales organization, Enzymatica intends to expand ColdZyme to more geographical markets through distribution agreements. A parallel objective of the company in the long term is to commercialize more enzyme based products in upper respiratory infections and oral health.

Net sales for 2014 were SEK 19.1 million, almost double the previous year. The positive trend continued into the first part of 2015, when the company reported continued strong sales growth. Sales in the first quarter of 2015 were SEK 7.0 million compared with SEK 2.5 million in the corresponding period of the previous year.

For more information please refer to the company description drawn up for the listing on Nasdaq First North. The document is available on the company's website www.enzymatica.se/IR.

For further information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB
Phone: +46 708 86 53 70 | Email: fredrik.lindberg@enzymatica.com

Lennart Nilsson, Chairman of the Board, Enzymatica AB
Phone: +46 46 286 31 00. Email: ir@enzymatica.se

About Enzymatica AB
Enzymatica is a life science company whose business concept is to offer effective aid against some of our most common diseases where viruses or bacteria play a decisive role. Over a short period the company has developed a unique oral spray for common colds, ColdZyme® and launched it on four markets. The product became the leading article for common cold in Swedish pharmacies during winter 2014-2015. The development program includes medical devices in upper respiratory infections and oral health, and veterinary products. The company is headquartered in Lund, Sweden. For more information, visit www.enzymatica.com.

Enzymatica's Certified Adviser is Erik Penser Bankaktiebolag.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire

HUG#1928226

ENZYMOTEC LTD. (NASDAQ:ENZY)
過去株価チャート
から 6 2024 まで 7 2024